JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

Overview of attention for article published in International Journal of Hematology, June 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial

Article in JMIR Research Protocols (February 2024)

The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial (Preprint)

Preprint in JMIR Preprints (November 2023)

Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Article in Japanese Journal of Clinical Oncology (July 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.